Approved indications: Opzelura is approved to treat mild to moderate atopic dermatitis (eczema) in non-immunocompromised adults and children 2 years and older whose disease is not adequately controlled with prescription topicals or when those are not advisable, and to treat nonsegmental vitiligo in adults and children 12 years and older.

Off-label uses: Clinicians may consider Opzelura off label for other inflammatory or pigmentary skin conditions (for example, some cases of alopecia areata or lichen planus), but current evidence is limited to small studies and case reports, and it is not FDA-approved for these uses.

Efficacy expectations:

• Atopic dermatitis: Many patients experience noticeable itch relief within the first few days and visible skin improvement over about 2–8 weeks, with the cream used intermittently for flares and stopped when clear.
• Vitiligo: Repigmentation is gradual; some people see early, faint color return after 8–12 weeks, and clinical trials showed meaningful facial and body repigmentation in a substantial portion of patients by 24 weeks, with further gains in many who continued up to about 1 year.
• Compared with similar drugs: Opzelura is a nonsteroidal option that can provide clearing comparable to mid-potency topical steroids or topical calcineurin inhibitors for some patients, without steroid-related skin thinning, but it carries class JAK inhibitor boxed warnings about rare serious systemic events, so long-term safety experience is more limited than with older agents.

General use instructions: Opzelura is for use on the skin only; apply a thin layer to clean, dry skin on affected areas, gently rub in until absorbed, avoid the eyes, inside the mouth, and inside the vagina, do not cover with tight occlusive bandages unless directed, and wash your hands after applying (unless treating the hands).

Atopic dermatitis dosing: For adults and children 12 years and older, apply a thin layer twice daily to affected areas covering up to 20% of the body surface, using no more than one 60 g tube per week or one 100 g tube every 2 weeks; for children 2–11 years, apply twice daily to up to 20% body surface area but do not use more than one 60 g tube every 2 weeks, and in all ages stop when signs and symptoms resolve and have the skin rechecked if there is little or no improvement after about 8 weeks.

Vitiligo dosing: For adults and children 12 years and older with nonsegmental vitiligo, apply a thin layer twice daily to depigmented areas of up to 10% of body surface area, including the face and some sensitive external areas as directed, without exceeding one 60 g tube per week or one 100 g tube every 2 weeks; meaningful repigmentation often takes more than 24 weeks, so your clinician may reassess around that time to decide whether to continue.

Special dosing instructions: Do not use Opzelura at the same time on the same areas with other JAK inhibitors, biologic immune-modulating drugs, or strong systemic immunosuppressants such as azathioprine or cyclosporine unless your prescriber specifically directs this, and avoid long-term continuous use over very large areas without medical supervision.

Missed dose and overdose: If you miss a dose, apply it as soon as you remember on that same day, but if it is almost time for the next application, skip the missed dose and resume your usual schedule without applying extra; if too much cream is applied, gently wipe off the excess, and if a large amount is swallowed or used over an excessively large area and you feel unwell (for example, fever, infection signs, chest pain, sudden shortness of breath, or severe headache), contact poison control (1-800-222-1222) or seek emergency care.

Common side effects: Most side effects are mild and occur where the cream is applied, including redness, itching, burning or stinging, acne, and small bumps or folliculitis; other reported effects include colds or upper respiratory infections, headache, urinary tract infection, diarrhea, and fever, which usually start in the first weeks of treatment and often improve as the skin adjusts.

Serious or rare adverse effects: Because ruxolitinib is a JAK inhibitor, there is a boxed warning (based largely on oral JAK data) for serious infections (such as tuberculosis, shingles, pneumonia), increased risk of certain cancers (including lymphoma and skin cancers), major cardiovascular events (heart attack, stroke), blood clots, and death; these events were uncommon in clinical trials of the cream, but new or worsening infections, chest pain, sudden shortness of breath, severe headache, weakness on one side, or unusual bruising or bleeding require immediate medical attention.

Warnings and precautions: Do not use Opzelura on areas with an active serious infection, and use caution if you have a history of recurrent infections, tuberculosis or hepatitis, blood clots, heart attack or stroke, cancer, or are a current or past long-term smoker; safety data are more limited in older adults, and the cream is not approved for atopic dermatitis in children under 2 years or for vitiligo in those under 12 years. During pregnancy or breastfeeding, use only if the expected benefit clearly outweighs potential risks, avoid applying it on the breast area that might contact an infant, and discuss alternatives with your clinician.

Overall safety compared with other treatments: Systemic absorption from the cream is low when used as directed, so serious systemic events appear rare, and Opzelura avoids steroid-specific issues such as skin thinning and stretch marks; however, its JAK class warning means clinicians may be more cautious in high-risk patients compared with older topical steroids or calcineurin inhibitors that have longer safety track records.

Reporting and staying updated: Side effects should be reported to your prescriber and can also be reported directly to the FDA MedWatch program (by phone at 1-800-FDA-1088 or online) for ongoing safety monitoring; updated safety communications and prescribing information are available on the FDA and manufacturer websites.

Drug and product interactions: Because Opzelura is applied to the skin, traditional drug–drug interactions are minimal, but using it together with other strong immune-suppressing medicines—such as oral JAK inhibitors, many biologic injections for autoimmune disease, or potent systemic immunosuppressants like cyclosporine or azathioprine—is not recommended unless specifically supervised by a specialist; routine use with moisturizers, gentle cleansers, and most over-the-counter products is acceptable, but you should avoid adding other prescription-strength steroid or calcineurin creams on the same area unless your prescriber advises it.

Food, alcohol, and procedures: There are no known interactions with foods, beverages, alcohol in moderation, or standard imaging contrast dyes when Opzelura is used as directed, though heavy alcohol use can worsen some skin conditions and overall health, which may indirectly affect treatment.

Precautions and higher-risk situations: Opzelura should not be started on areas with an active serious infection, and clinicians use caution in people with a history of tuberculosis or chronic viral hepatitis, frequent or severe infections, blood clots, heart attack or stroke, certain cancers (especially lymphomas or skin cancers), older age, or long-term smoking; use is not established in children under 2 years for atopic dermatitis or under 12 years for vitiligo.

Monitoring needs: Routine blood testing is not required for most healthy patients using Opzelura on limited areas, but for those at higher risk or using it long term on larger areas, clinicians may consider baseline and periodic checks such as complete blood counts, lipids, and skin cancer screening, and all patients should be monitored for signs of infection, blood clots, or heart problems and have therapy reviewed regularly.

Q: Is Opzelura a steroid cream?
A: No, Opzelura is not a steroid; it contains ruxolitinib, a targeted Janus kinase (JAK) inhibitor that works on specific immune signals in the skin, so it can help avoid steroid-related side effects like skin thinning.

Q: How long does it take for Opzelura to work for eczema?
A: Some people notice less itching within a few days and clearer skin over 2–8 weeks, but if your atopic dermatitis has not improved after about 8 weeks of regular use, you should check back with your prescriber.

Q: How long before I see repigmentation with Opzelura for vitiligo?
A: Repigmentation is slow and gradual, often taking 8–12 weeks to see early color changes and 6 months or longer to judge full benefit, and not everyone responds to the same degree.

Q: Can I use Opzelura on my face or sensitive areas?
A: Opzelura can be used on many facial and external sensitive areas as directed, but it should not be placed in the eyes, inside the mouth, or inside the vagina, and you should tell your clinician if you experience significant burning or irritation.

Q: Can I use moisturizers or other creams with Opzelura?
A: Yes, you can usually use gentle moisturizers and cleansers with Opzelura; many clinicians suggest applying Opzelura first, allowing it to absorb, and then applying moisturizer, but you should avoid adding other prescription immunosuppressant creams on the same spots unless your prescriber instructs you.

Q: Will I need blood tests while using Opzelura?
A: Most people using Opzelura on limited areas do not need routine blood tests, but your clinician may order labs or other monitoring if you have risk factors (such as a history of blood clots, heart disease, or cancer) or if you use the cream long term on larger areas.

Storage: Store Opzelura cream at room temperature 68°F to 77°F (20°C to 25°C), keep the tube tightly closed, protect it from excessive heat, moisture, and direct sunlight, do not refrigerate or freeze it, and always keep it out of reach of children and pets.

Disposal: When the tube is empty, expired, or your prescriber tells you to stop, use a local medicine take-back program if available, or mix any leftover cream (without flushing it down the toilet or sink) with an undesirable substance such as used coffee grounds or cat litter, seal it in a bag or container, and place it in the household trash according to local regulations.